Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.63 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.63 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.63 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.63 |
| ▸ | HRH1 | P35367 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17779410 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL17270088 | 1.00 | DPP4 (0.63) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL15579156 | 0.93 | DPP4 (0.62) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2855639 | 0.93 | DPP4 (0.64) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2854108 | 0.93 | DPP4 (0.65) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2856794 | 0.93 | DPP4 (0.64) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2858953 | 0.93 | DPP4 (0.64) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2849971 | 0.92 | DPP4 (0.65) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2857185 | 0.91 | DPP4 (0.65) | DPP4DPP8DPP9PTGS2HRH1 | |
| SCHEMBL2851871 | 0.90 | DPP4 (0.65) | DPP4DPP8DPP9PTGS2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854795-B1 | Salt of a proline derivative, solvate thereof, and production method thereof | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-06-01 | — | — | EP | claimed |
| US-8003790-B2 | Salt of proline derivative, solvate thereof, and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | claimed |
| US-20090216016-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2009-08-27 | — | — | US | claimed |
| EP-1854795-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-14 | — | — | EP | claimed |
| EP-1854795-B1 | Salt of a proline derivative, solvate thereof, and production method thereof | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-06-01 | — | — | EP | disclosed |
| WO-2015173779-A1 | PROCESS FOR THE PREPARATION OF TENELIGLIPTIN AND ITS NOVEL INTERMEDIATES | MICRO LABS LIMITED (IN) | 2015-11-19 | — | — | WO | disclosed |
| WO-2015132679-A1 | TENELIGLIPTIN COMPOSITIONS | GLENMARK PHARMACEUTICALS LTD (IN) | 2015-09-11 | — | — | WO | disclosed |
| US-8604198-B2 | Salt of proline derivative, solvate thereof, and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-12-10 | — | — | US | disclosed |
| EP-2602259-A2 | Salt of proline derivative, solvate thereof, and production method thereof | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-06-12 | — | — | EP | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-20110282058-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-11-17 | — | — | US | disclosed |
| US-8003790-B2 | Salt of proline derivative, solvate thereof, and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-23 | — | — | US | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| EP-1854795-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | MITSUBISHI PHARMA CORPORATION (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110282058-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | DPP4, DPP3, PEPD | DPP4 1/4885DPP8 6/4885DPP9 8/4885 |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 5/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | DPP4 1/4885DPP8 6/4885DPP9 4/4885 |
| US-20090216016-A1 | SALT OF PROLINE DERIVATIVE, SOLVATE THEREOF, AND PRODUCTION METHOD THEREOF | DPP4, DPP3, PEPD | DPP4 1/4885DPP8 6/4885DPP9 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.